Celdara Medical (OnCyte) Overview
Status
Acquired/Merged
Latest Deal Type
M&A
Financing Rounds
1
Celdara Medical (OnCyte) General Information
Description
Developer of treatments in the field of immuno-oncology. The business unit has developed the most advanced autologous CAR (chimeric antigen receptor) T-Cell drug candidate uses a specific human Natural Killer cell receptor that targets tumor antigens expressed in most liquid and solid cancers.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- Lebanon, NH
- United States
Celdara Medical (OnCyte) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Celdara Medical (OnCyte)‘s full profile, request access.
Request a free trial
Celdara Medical (OnCyte) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Celdara Medical (OnCyte)‘s full profile, request access.
Request a free trial